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Reliance on imaging to determine therapeutic responses in both clinical practice and clinical trials is ever increas-
ing. When used in advanced, unresectable lung cancer, imag-
ing interpretation helps guide the oncologist on the utility of 
continuing the patient’s current systemic therapy or changing 
treatment. In general, the two main imaging modalities used 
to assess treatment response in lung cancer patients are com-
puterized tomography (CT) and [18]F-flourodeoxyglucose 
(FDG) positron emission tomography (PET). PET imaging 
can predict tumor response early in the treatment course and 
possibly shorten treatment in oncology patients responding 
to therapy; alternatively, imaging provides the opportunity to 
adjust treatment in cancer patients not responding to therapy. 
Such is a strategy now employed in Hodgkin’s lymphoma 
where risk-adapted treatment uses PET/CT after two cycles 
of chemotherapy to determine treatment benefit and mitigate 
long-term harm.1
Although both CT and PET can be used to evaluate 
tumor response, each modality measures different aspects of 
the tumor. CT uses ionizing radiation to depict the anatomical 
features of a tumor. Although it is highly sensitive, it cannot 
distinguish viable malignant cells from nonmalignant areas 
of tissue that are often times present after treatment and can 
be confused with tumor. However, PET provides functional 
information based on the tumor biology and uptake of PET 
specific imaging probes such as FDG. FDG is a glucose ana-
log where oxygen at the C-2 position is replaced with 18-fluo-
rine. FDG, like glucose, is actively transported into the cell by 
glucose transport proteins. Once glucose and FDG are in the 
cell, they are phosphorylated by hexokinases. Under normal 
conditions, phosphorylated glucose continues along the gly-
colytic pathway for energy production. However, FDG cannot 
be further processed and is trapped intracellularly as FDG-6-
phosphate. Thus, FDG accumulates in areas with high levels 
of metabolism and glycolysis, such as sites of inflammation, 
tissue repair, hyperactivity (e.g., muscle), and—of particu-
lar interest—in cancer cells, which are often highly meta-
bolically active and favor inefficient anaerobic pathways. In 
cancer, these increases in glucose demands lead to increased 
uptake of FDG and increased intracellular retention of FDG-
6-phosphate in tumor cells relative to normal cells.
Two distinct advantages of PET over CT are PET’s abil-
ity to more rapidly assess treatment response and quantita-
tively determine the magnitude of tumor metabolic change. 
For example, when treatment with imatinib is initiated in gas-
trointestinal stromal tumors, FDG uptake decreases within 
hours2,3 with dramatic reduction in FDG metabolism. Rapid 
decrease in FDG uptake has been observed within 2 hours in 
EGFR mutant non–small-cell lung cancer cells treated with 
gefitinib.4,5
Quantitation of FDG uptake on PET is generally 
divided into two types of analysis: dynamic-compartmental 
analysis to determine the kinetic parameter of uptake and the 
more routine static semiquantitative approach using standard-
ized uptake values (SUV). SUV is obtained automatically on 
most modern-day PET/CT scanners and measures normalized 
radioactivity concentration as follows:
 
SUV
activity concentration in tissue
injected activity body size
=
/
SUVmean and SUVmax of a target lesion or a region of 
interest are the two most common ways of reporting SUV. 
SUVmean is less sensitive to image noise as it incorporates 
voxel information from multiple locations.6 SUVmean is 
dependent on the voxels that are selected, and therefore, sub-
ject to intra- and interobserver variability.6 SUVmax reports 
the highest voxel value within the region of interest and is 
more susceptible to image noise6 and can provide less intra- 
and interobserver variability. Whether SUVmean or SUVmax 
values are used, SUVs can provide a convenient marker of 
glucose metabolism, reflecting the presence or absence of 
metabolically active malignancy. However, the accuracy and 
reproducibility of SUVs can vary considerably.
Biological factors that can affect SUV measurements 
include patient weight composition (heavier patients have 
higher SUV values), body-size calculation (weight loss can 
decrease SUV values leading to false-positive treatment 
response), blood glucose level (after glucose loading, SUV 
can decrease by > 50%), postinjection uptake time (increase 
of ≤30% SUV if measured at 4 hours versus measurement at 
1 hour), respiratory motion (can alter SUV by ≤ 30%),6 lesion 
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size (small lesions are more susceptible to count recovery 
issues, leading to lower SUVs than larger lesions are), motion 
artifacts from patient discomfort, and inflammation.7
Technical factors that can affect SUV measurements 
include variability of the scanner, image-reconstruction 
parameters, calibration and/or timing mismatch error between 
the scanner and the FDG dose calibrator, use of contrast mate-
rial for PET/CT, residual activity in the administration system 
or syringe, and intra- and interobserver variability.6,7
Individually, each of these factors may affect SUV cal-
culations by 5% to 50%. Cumulatively, these factors could 
lead to erroneous interpretation of response to therapy, and 
result in inappropriate continuation of ineffective therapy 
or premature discontinuation of effective therapy. With so 
many technical and biological factors that can each individu-
ally result in altered SUV measurements, how can a treating 
oncologist be sure that PET/CT reports are reliable for making 
treatment decisions? Some potential solutions to these techni-
cal and biological factors that can mitigate false interpretation 
of PET/CT readings are included in Table 1. Although most of 
these factors are outside the control of a thoracic oncologist, 
knowledge of these factors can provide reference for the reli-
ability of reported changes in SUV values. However, as more 
PET imaging is migrating away from radiology centers and 
academic institutions toward privately held oncology prac-
tices, it becomes incumbent on the treating oncologists who 
own their own equipment to have some basic knowledge of 
the pitfalls in PET imaging.
Furthermore, although there are guidelines and crite-
ria for evaluating response using CT in solid tumors,8 similar 
criteria for PET are less established. Recently, there have been 
attempts to better standardize criteria for PET interpretation 
using European Organisation for Research and Treatment 
of Cancer (EORTC) and/or Positron Emission Tomography 
Response Criteria In Solid Tumors (PERCIST 1.0) criteria.9 In 
particular, both the EORTC and PERCIST 1.0 are published 
guidelines for comparing FDG PET response results in multi-
center trials and for declaring categorical treatment responses 
based on threshold changes in SUVs after treatment, of which 
there are four categories: complete metabolic response, partial 
metabolic response, stable metabolic disease, and progressive 
metabolic disease. Although PERCIST 1.0 provides more 
specific instructions about what constitutes a target lesion and 
treatment response, a large, multicenter, prospective compari-
son has not yet been conducted to validate either methodology. 
In this regard, we recently showed that there was no significant 
difference in categorical response rates between EORTC and 
PERCIST 1.0 on FDG PET/CT in subjects with metastatic 
basal cell carcinoma treated with vismodegib.10
Nevertheless, when the various biological and technical 
factors that can drastically affect the reading and interpretation 
of a PET/CT are not controlled, the interpretation of PET 
images becomes problematic. Does this negate the added value 
of PET imaging for determining treatment response to therapy? 
No. It does, however, require that the treating oncologist be 
aware of these issues and be cautious to solely make treatment 
decisions based on SUV measurements alone. In addition, it 
is important that each oncologist work cooperatively with the 
interpreting radiology or nuclear medicine team to make sure 
that each and every one is paying close attention to the details 
TABLE 1.  Recommendations for Factors Affecting PET/CT Interpretation
Factor Affecting Interpretation Recommendation SUV Variability without 
Recommendation
A. Before patient scans Scanner variability Use the same PET/CT scanner for baseline 
and follow-up (where possible).
 ≤ 22.6%6
Calibration and/or timing mismatch error 
between the scanner and the FDG dose 
calibrator
Calibrate the FDG dose calibrators and 
synchronize dose calibrator clocks with  
the scanner clocks.
≤ 10%6
Patient body-size calculation Weigh every patient with a calibrated scale 
before imaging.
Not available, but could observe 11% 
decrease in weight while on therapy11
Blood glucose level Obtain serum glucose before each PET scan 
and as an additional quality assurance 
mechanism, record average SUV in the 
liver.
≤ 50%12
B. During the scan Residual activity in the administration 
system or syringe
Measure residual FDG activity in the 
injection tubing and syringe to accurately 
determine the dose administered.
≤ 5%7
Postinjection uptake time Use a minimum uptake time of 60 minutes. 
Keep the uptake time the same as the 
baseline scan (+/− 10 min).
≤ 30%6
Reconstruction parameter changes Use the same acquisition technique and 
reconstruction parameters for baseline and 
follow-up scans. Use the same CT protocol 
for PET image attenuation correction.
≤ 12%6
C. After the scan Intra- and interobserver variability Use screen saves or other documentation 
to improve the marked region of interest 
reproducibility.
≤ 17%6
PET, positron emission tomography; CT, computerized tomography; FDG, flourodeoxyglucose; SUV, standardized uptake values.
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before, during, and after a patient undergoes PET imaging. 
Only in this manner can PET interpretation realize its full 
potential in lung cancer.
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